Biogen Says New MS Drug Does Well in Clinical Trials

Some hopeful news for those who suffer from multiple sclerosis. Biogen announced that new data for its Tecfidera boded well for the drug in clinical and real-world settings, the Wall Street Journal reports. Biogen said that “the drug significantly reduced the time to a first relapse versus other treatments.”

As Managed Care reported a few months ago, the breakthroughs and developments in MS treatments are coming at a fast pace. But we also mentioned the challenges, as the “skewed MS drug development reflects both the complex nature of the disease and an understanding of its pathology that is still incomplete.”